Elite in Non-Alcoholic Fatty Liver Disease

Dr. Mary E. Rinella

Hepatology
University Of Chicago
355 E Grand Ave, 
Chicago, IL 
Accepting New Patients
Offers Telehealth
27 Years of Experience
Elite in Non-Alcoholic Fatty Liver Disease
University Of Chicago
355 E Grand Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mary Rinella is a Hepatologist in Chicago, Illinois. Dr. Rinella has been practicing medicine for over 27 years and is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. Her top areas of expertise are Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Cirrhosis, Liver Transplant, and Endoscopy. Dr. Rinella is currently accepting new patients.

Her clinical research consists of co-authoring 159 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 133 articles and participated in 8 clinical trials in the study of Non-Alcoholic Fatty Liver Disease.

Specialties
Hepatology
Licenses
Internal Medicine in IL
Hospital Affiliations
The University Of Chicago Medical Center
Northshore University Healthsystem - Evanston Hospital
Languages Spoken
English
French
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

UNIVERSITY OF CHICAGO
355 E Grand Ave, Chicago, IL 60611
Other Locations
UNIVERSITY OF CHICAGO
200 Berteau Ave, Elmhurst Hospital, Elmhurst, IL 60126
UNIVERSITY OF CHICAGO
400 Skokie Blvd, Suite 300, Northbrook, IL 60062
UNIVERSITY OF CHICAGO
5841 S Maryland Ave, Chicago, IL 60637

Additional Areas of Focus

Dr. Rinella has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Enrollment Status: Completed
Publish Date: December 20, 2022
Intervention Type: Device
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 07, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients
A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients
Enrollment Status: Completed
Publish Date: May 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

159 Total Publications

The People-First Liver Charter.
The People-First Liver Charter.
Journal: Nature medicine
Published: June 05, 2025
Similar Doctors
Michael R. Charlton
Elite in Non-Alcoholic Fatty Liver Disease
Dr. Michael R. Charlton
Hepatology
Elite in Non-Alcoholic Fatty Liver Disease
Dr. Michael R. Charlton
Hepatology

University Of Chicago

5841 S Maryland Ave, 
Chicago, IL 
 (7.1 mi)
773-702-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Charlton is a Hepatologist in Chicago, Illinois. Dr. Charlton and is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Cirrhosis, Liver Transplant, and Islet Cell Transplantation. Dr. Charlton is currently accepting new patients.

Distinguished in Non-Alcoholic Fatty Liver Disease
Dr. Scott J. Cotler
Hepatology
Distinguished in Non-Alcoholic Fatty Liver Disease
Dr. Scott J. Cotler
Hepatology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (11.4 mi)
708-216-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Scott Cotler is a Hepatologist in Maywood, Illinois. Dr. Cotler and is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Hepatitis, Hepatitis C, Liver Cancer, Liver Transplant, and Endoscopy. Dr. Cotler is currently accepting new patients.

Distinguished in Non-Alcoholic Fatty Liver Disease
Dr. Eric R. Kallwitz
Hepatology
Distinguished in Non-Alcoholic Fatty Liver Disease
Dr. Eric R. Kallwitz
Hepatology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (11.4 mi)
708-216-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Eric Kallwitz is a Hepatologist in Maywood, Illinois. Dr. Kallwitz and is rated as a Distinguished provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Visceromegaly, Cirrhosis, Liver Transplant, and Endoscopy. Dr. Kallwitz is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rinella's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile